Testing a treatment made from a patient's own immune cells for glioblastoma that has come back
Official title: Safety and Efficacy of Autologous Natural Killer Cell Therapy (CHANK-101) in Patients With Recurrent Glioblastoma
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on .
The short version
This study tests whether a patient's own immune cells, grown and given back, can help against glioblastoma: A glioma that is given grade 4. Grade 4 is the highest grade there is. The tumor grows fast. Treatment usually starts soon after it is found. It often means surgery, and then radiation and chemotherapy. See the glossary that has returned.
Read our full plain-language summary
What the trial team says
This multicenter, open-label, externally controlled clinical study is designed to evaluate the safety and efficacy of CHANK-101, an autologous natural killer (NK) cell therapy, in patients with recurrent glioblastoma. The primary objective is to evaluate progression-free survival (PFS) following CHANK-101 administration. Secondary objectives include evaluating safety and tolerability, progression-free survival at 6 months (PFS-6), and overall survival (OS).
Key facts
- Registry number
- NCT07831161
- Stage of testing
- Not applicable
- Conditions studied
- Recurrent Glioblastoma
Where it is running
This trial lists 4 sites.
-
Busan
- Dong-A University Hospital (Busan)
-
Gyeonggi-do
- CHA Bundang Medical Center (Seongnam-si)
-
Seoul
- Asan Medical Center (Seoul)
- Gangnam Severance Hospital (Seoul)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.